Gilead’s Livdelzi (Seladelpar) for Primary Biliary Cholangitis Promises Pruritus Reduction

The US Food and Drug Administration (FDA) has given the nod to Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC), a rare autoimmune disease that primarily affects women.

PBC gradually destroys the bile ducts in the liver, leading to inflammation, scarring and, if untreated, potentially liver failure. For the 130,000 Americans living with this condition, many find existing treatments either ineffective or hard to tolerate.